Total Payments
$141,617
2024 Payments
$39.79
Companies
20
Transactions
173
Medicare Patients
744
Medicare Billing
$95,204
Payment Breakdown by Category
Consulting$58,520 (41.3%)
Other$49,752 (35.1%)
Travel$28,374 (20.0%)
Food & Beverage$4,624 (3.3%)
Research$330.00 (0.2%)
Education$16.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,520 | 24 | 41.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,917 | 15 | 32.4% |
| Travel and Lodging | $28,374 | 65 | 20.0% |
| Food and Beverage | $4,624 | 65 | 3.3% |
| Honoraria | $3,835 | 2 | 2.7% |
| Unspecified | $330.00 | 1 | 0.2% |
| Education | $16.75 | 1 | 0.0% |
Payments by Type
General
$141,287
172 transactions
Research
$330.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $35,401 | 28 | $0 (2020) |
| Gilead Sciences, Inc. | $34,334 | 40 | $0 (2020) |
| AbbVie, Inc. | $17,476 | 24 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $11,850 | 21 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $7,899 | 11 | $0 (2019) |
| Janssen Biotech, Inc. | $5,918 | 8 | $0 (2020) |
| Genentech USA, Inc. | $5,028 | 6 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $4,838 | 7 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $4,025 | 2 | $0 (2018) |
| Epizyme, Inc., | $3,835 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39.79 | 1 | Rigel Pharmaceuticals, Inc. ($39.79) |
| 2021 | $5,295 | 4 | BeiGene, Ltd. ($1,950) |
| 2020 | $17,618 | 13 | Celgene Corporation ($8,363) |
| 2019 | $37,398 | 49 | Celgene Corporation ($22,991) |
| 2018 | $26,309 | 49 | Gilead Sciences, Inc. ($9,253) |
| 2017 | $54,957 | 57 | Gilead Sciences Inc ($19,837) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/11/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $39.79 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/21/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2021 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | ||||||
| 01/27/2021 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 01/22/2021 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,515.00 | General |
| Category: Oncology | ||||||
| 12/23/2020 | Epizyme, Inc., | TAZVERIK (Drug) | Honoraria | Cash or cash equivalent | $1,770.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,845.00 | General |
| 11/19/2020 | Bayer HealthCare Pharmaceuticals Inc. | Aliqopa (Drug) | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| Category: Oncology | ||||||
| 09/28/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| Category: Oncology | ||||||
| 09/07/2020 | Seagen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| 08/18/2020 | Epizyme, Inc., | TAZVERIK (Drug) | Honoraria | Cash or cash equivalent | $2,065.00 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2020 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $868.44 | General |
| Category: Hematology | ||||||
| 03/16/2020 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $1,302.80 | General |
| Category: Hematology | ||||||
| 03/12/2020 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,875.00 | General |
| Category: Hematology | ||||||
| 03/12/2020 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $1,187.96 | General |
| Category: Hematology | ||||||
| 03/05/2020 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | Cash or cash equivalent | $129.11 | General |
| Category: Hematology | ||||||
| 01/23/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.00 | General |
| 01/19/2020 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Education | In-kind items and services | $16.75 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| 12/08/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $70.97 | General |
| Category: Oncology | ||||||
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $730.66 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $217.26 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $90.00 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $36.83 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 74 | 128 | $49,434 | $11,231 |
| 2022 | 3 | 55 | 84 | $32,310 | $7,340 |
| 2021 | 2 | 175 | 238 | $81,984 | $14,050 |
| 2020 | 8 | 440 | 985 | $299,180 | $62,583 |
Total Patients
744
Total Services
1,435
Medicare Billing
$95,204
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 80 | $25,440 | $5,593 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 30 | $12,870 | $3,266 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $11,124 | $2,373 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 54 | $17,172 | $3,715 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 18 | $7,722 | $1,945 | 25.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $7,416 | $1,680 | 22.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 217 | $69,006 | $11,697 | 17.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $12,978 | $2,353 | 18.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 245 | 656 | $196,748 | $35,840 | 18.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 129 | $35,604 | $10,479 | 29.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 54 | 54 | $31,664 | $6,800 | 21.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 20 | $9,440 | $3,155 | 33.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 34 | 38 | $6,536 | $2,149 | 32.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 38 | $6,422 | $2,140 | 33.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 35 | 36 | $7,155 | $1,098 | 15.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 13 | 14 | $5,611 | $921.37 | 16.4% |
About Dr. Nishitha Reddy, M.D
Dr. Nishitha Reddy, M.D is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1710177654.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nishitha Reddy, M.D has received a total of $141,617 in payments from pharmaceutical and medical device companies, with $39.79 received in 2024. These payments were reported across 173 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($58,520).
As a Medicare-enrolled provider, Reddy has provided services to 744 Medicare beneficiaries, totaling 1,435 services with total Medicare billing of $95,204. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Nashville, TN
- Active Since 07/26/2007
- Last Updated 10/03/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710177654
Products in Payments
- Revlimid (Drug) $34,151
- Zydelig (Drug) $26,290
- IMBRUVICA (Drug) $12,256
- Non-Covered $6,331
- Aliqopa (Drug) $5,519
- Venclexta (Drug) $5,362
- Rituxan (Biological) $5,028
- OPDIVO (Biological) $4,025
- TAZVERIK (Drug) $3,835
- CALQUENCE (Drug) $2,285
- Rezlidhia (Drug) $39.79
- ELZONRIS (Drug) $16.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Dr. Jonathan Abbas, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Jesus Berdeja, M.d, M.D
Hematology & Oncology — Payments: $572,989
Hematology & Oncology $572,989
Dr. Krish Patel, M.d, M.D
Hematology & Oncology — Payments: $568,657
Hematology & Oncology $568,657